Koers Oramed Pharmaceuticals, Inc. Xetra
Aandelen
OJU
US68403P1049
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- EUR | - |
|
Omzet 2024 * | 750K 698K | Omzet 2025 * | 2 mln. 1,86 mln. | Marktkapitalisatie | 91,01 mln. 84,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - 0 | Nettowinst (verlies) 2025 * | -14 mln. -13,03 mln. | EV/omzet 2024 * | 121 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 45,5 x |
K/w-verhouding 2024 * |
-224
x | K/w-verhouding 2025 * |
-6,79
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,73% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 12-04-02 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 12-04-02 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 14-04-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 12-04-02 |
Miriam Kidron
FOU | Founder | 83 | 12-04-02 |
Leonard Sank
BRD | Director/Board Member | 59 | 23-10-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,71% | 52,85 mld. | |
-7,73% | 38,87 mld. | |
+35,40% | 38,24 mld. | |
-10,77% | 26,79 mld. | |
+11,66% | 26,16 mld. | |
-18,26% | 19,9 mld. | |
+38,38% | 13,18 mld. | |
+28,97% | 12,24 mld. | |
-3,51% | 11,79 mld. |
- Beurs
- Aandelen
- Koers ORMP
- Koers OJU